4 years ago

Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques

Young C. Shin, Matthias Pauthner, John D. Altman, Ronald C. Desrosiers, Lucas Gonzalez-Nieto, Nuria Pedreño-Lopez, Eva Rakasz, Varian Bailey, Diogo M. Magnani, Maoli Yuan, David I. Watkins, Dennis R. Burton, Iris Castro, Martin J. Gutman, Keisuke Ejima, Dillon Betancourt, Jeffrey D. Lifson, David B. Allison, David T. Evans, Saverio Capuano III, Christopher L. Parks, Michael Ricciardi, Aline Domingues, Glen N. Barber, Benjamin von Bredow, Helen S. Maxwell, Mauricio A. Martins

by Mauricio A. Martins, Young C. Shin, Lucas Gonzalez-Nieto, Aline Domingues, Martin J. Gutman, Helen S. Maxwell, Iris Castro, Diogo M. Magnani, Michael Ricciardi, Nuria Pedreño-Lopez, Varian Bailey, Dillon Betancourt, John D. Altman, Matthias Pauthner, Dennis R. Burton, Benjamin von Bredow, David T. Evans, Maoli Yuan, Christopher L. Parks, Keisuke Ejima, David B. Allison, Eva Rakasz, Glen N. Barber, Saverio Capuano III, Jeffrey D. Lifson, Ronald C. Desrosiers, David I. Watkins

The ability to control lentivirus replication may be determined, in part, by the extent to which individual viral proteins are targeted by the immune system. Consequently, defining the antigens that elicit the most protective immune responses may facilitate the design of effective HIV-1 vaccines. Here we vaccinated four groups of rhesus macaques with a heterologous vector prime/boost/boost/boost (PBBB) regimen expressing the following simian immunodeficiency virus (SIV) genes: env, gag, vif, rev, tat, and nef (Group 1); env, vif, rev, tat, and nef (Group 2); gag, vif, rev, tat, and nef (Group 3); or vif, rev, tat, and nef (Group 4). Following repeated intrarectal challenges with a marginal dose of the neutralization-resistant SIVmac239 clone, vaccinees in Groups 1–3 became infected at similar rates compared to control animals. Unexpectedly, vaccinees in Group 4 became infected at a slower pace than the other animals, although this difference was not statistically significant. Group 1 exhibited the best post-acquisition virologic control of SIV infection, with significant reductions in both peak and chronic phase viremia. Indeed, 5/8 Group 1 vaccinees had viral loads of less than 2,000 vRNA copies/mL of plasma in the chronic phase. Vaccine regimens that did not contain gag (Group 2), env (Group 3), or both of these inserts (Group 4) were largely ineffective at decreasing viremia. Thus, vaccine-induced immune responses against both Gag and Env appeared to maximize control of immunodeficiency virus replication. Collectively, these findings are relevant for HIV-1 vaccine design as they provide additional insights into which of the lentiviral proteins might serve as the best vaccine immunogens.

Publisher URL: http://journals.plos.org/plosone/article

DOI: 10.1371/journal.ppat.1006529

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.